shutterstock_1438793243 (1)

Study Information

The purpose of this study is to evaluate the safety and immunogenicity of an investigational live-attenuated Chikungunya vaccine verses a placebo.  The investigational vaccine is being developed to prevent CHIKV infection in the general population living in endemic regions as well as to serve as a prophylactic measure for travelers who are going to areas affected. 

Duration: Up to 7 months 

Number of visits to AMR Lexington: Up to 6

Compensation is available for time and travel.

Qualifications:

Participants must be a healthy adult at least 18 years of age. Participants must also be willing and able to follow the clinical trial directions and procedures.  Other criteria also apply but will be addressed later in a qualifying questionnaire. 


If you are interested in participating in this study, please fill out the form below.  This will help us determine if you meet some of the initial criteria necessary to participate.  We will contact you within 48 hours to follow up and clarify any questions that you, or we, may have.  The information you provide is entered in our secure, password protected database which can only be accessed by authorized AMR Lexington personnel, unless given your permission or except as required by law.  The provided information will only be used to contact you to tell you more about this and any future study. Your contact information will remain within our database indefinitely unless otherwise requested.   

Pre-Qualifying Questionnaire

By submitting this information, AMR Lexington has my permission to contact me.  My consent allows AMR Lexington to use phone, text and email messages to contact me.  Message and data rates may apply.  I may contact AMR Lexington any time to change these preferences. To be removed or to change your contact preferences, please call an AMR Lexington recruitment specialist at 859-264-8999.

×

Make an appointment and we’ll contact you.